Sat. Nov 28th, 2020

FDA allows wide use of plasma for COVID-19 with little data that it works

Last week, the U.S. Food and Drug Administration (FDA) announced that it would not allow widespread use of blood plasma to treat COVID-19 patients without more evidence that the therapy works.

Yesterday (Aug. 23), the agency apparently reversed this decision and issued an “emergency use authorization” for the treatment, according to a statement. An emergency use authorization does not require as much clinical evidence as full FDA approval, but does allow doctors to administer an experimental treatment “when there are no adequate, approved and available alternatives,” according to the agency’s website. That means doctors can use clinical judgment to prescribe plasma without enrolling recipients in a clinical trial to test its effectiveness.